Long-Acting Anti-Influenza Monoclonal Antibody Platform Targets Immunocompromised Patients
RQ Bio announced the successful completion of an oversubscribed $115 million Series A financing, led by Frazier Life Sciences, to advance its long-acting antibody platform for influenza prevention. The financing will support IND-enabling development…
